Want to see HK:2257 full AI Analyst Report?
Sirnaomics Ltd. (2257) AI Stock Analysis
Top Page
Sirnaomics Ltd.
(HKEX:2257)
The score is primarily held down by weak financial performance: zero revenue in 2025, continued losses and cash burn, and a high-risk balance sheet with negative shareholder equity. Technicals also detract, with the stock trading below all major moving averages and negative momentum indicators. Valuation provides limited support due to negative earnings and no stated dividend yield.
Sirnaomics Ltd. (2257) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 459.81M
- Dividend Yield
- ―
- Average Volume (3M)
- 46.76K
- Price to Earnings (P/E)
- -4.8
- Beta (1Y)
- 0.90
- Revenue Growth
- -100.00%
- EPS Growth
- 30.94%
- Country
- Hong Kong
- Employees
- 37
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sirnaomics Ltd. Business Overview & Revenue Model
Company Description
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant med...
How the Company Makes Money
null
Sirnaomics Ltd. Financial Statement Overview
Summary
Financial statements indicate an early-stage biotech with very small and volatile revenue (dropping to zero in 2025), ongoing operating and net losses, and consistently negative operating/free cash flow. Although losses and cash burn improved materially in 2024–2025, the shift to negative shareholder equity and a shrinking asset base are major balance-sheet risk signals and increase reliance on external funding.
Income Statement
18Very NegativeBalance Sheet
22NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 1.78M | 397.00K | 705.00K | 0 |
| Gross Profit | -1.55M | -1.84M | 1.20M | 397.00K | 705.00K | -12.67M |
| EBITDA | -12.39M | -13.53M | -30.23M | -70.99M | -87.19M | -1.67B |
| Net Income | -10.63M | -14.42M | -51.38M | -78.69M | -88.30M | -1.66B |
Balance Sheet | ||||||
| Total Assets | 13.42M | 20.60M | 28.33M | 75.79M | 163.93M | 240.65M |
| Cash, Cash Equivalents and Short-Term Investments | 7.19M | 13.52M | 11.77M | 43.93M | 105.23M | 211.99M |
| Total Debt | 25.26M | 9.31M | 8.06M | 8.85M | 10.76M | 7.04M |
| Total Liabilities | 34.50M | 45.09M | 44.33M | 51.33M | 52.37M | 30.36M |
| Stockholders Equity | -6.06M | -9.91M | -1.68M | 40.20M | 122.01M | 211.62M |
Cash Flow | ||||||
| Free Cash Flow | -9.11M | -9.25M | -19.84M | -72.03M | -107.54M | -62.85M |
| Operating Cash Flow | -9.10M | -9.20M | -19.73M | -70.29M | -88.71M | -56.97M |
| Investing Cash Flow | -1.41M | 23.00K | 2.14M | -5.35M | -32.61M | -6.04M |
| Financing Cash Flow | 10.75M | 10.95M | 5.82M | -5.61M | 15.89M | 170.96M |
Sirnaomics Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2257, the sentiment is Positive. The current price of 4.13 is above the 20-day moving average (MA) of 3.92, above the 50-day MA of 3.89, and below the 200-day MA of 5.55, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 57.24 is Neutral, neither overbought nor oversold. The STOCH value of 73.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2257.
Sirnaomics Ltd. Peers Comparison
Overall Rating
HK:996652Neutral
HK:685550.1Neutral
HK:116748Neutral- HK:225742Neutral
HK:217139Underperform
HK:662837Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6855 | 50Neutral | HKD 10.12B | -5.93 | -153.78% | ― | 70.26% | -12.79% |
| HK:1167 | 48Neutral | HKD 3.62B | 6.00 | 47.76% | ― | 286.20% | ― |
| HK:2257 | 42Neutral | HKD 463.21M | -4.83 | 133.13% | ― | -100.00% | 30.94% |
| HK:2171 | 39Underperform | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
| HK:6628 | 37Underperform | HKD 327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2257 | Sirnaomics Ltd. | 4.13 | -5.64 | -57.73% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:1167 | Jacobio Pharmaceuticals Group Co., Ltd. | 4.60 | -2.66 | -36.64% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:6628 | Transcenta Holding Limited | 0.73 | -2.31 | -75.90% | |
| HK:6855 | Ascentage Pharma Group International | 27.20 | -40.70 | -59.94% |
Sirnaomics Ltd. Corporate Events
Sirnaomics Sues Former Management Over US$20 Million Investment
Sirnaomics Ltd. has filed a Writ of Summons in the High Court of Hong Kong against former members of its management team, including Dr. Lu Yang, Dr. Xiaochang Dai and Mr. Yip Wing Kei, in relation to the group’s approximately US$20 million inve...
Sirnaomics Sets Late‑August Board Meeting to Approve Interim 2026 Results
Sirnaomics Ltd. has scheduled a board meeting for August 28, 2026, to review and approve the interim results for the six months ended June 30, 2026, and to authorize their publication. The announcement signals an upcoming update on the company’...
Sirnaomics Completes HK$11.3 Million Share Subscription Under General Mandate
Sirnaomics Ltd. has completed a share subscription under its general mandate, issuing 2,435,600 new shares at HK$4.69 each to a single subscriber, raising net proceeds of approximately HK$11.3 million. The funds will be used as general working capita...
Sirnaomics Hits Phase II Milestone for RNA-Based Aesthetic Fat-Reduction Therapy
Sirnaomics Ltd. has reported the completion of first-patient dosing in its Phase II multi-center clinical trial of STP705 for medical aesthetic use, marking a notable clinical milestone for its RNA-based aesthetic pipeline. The study aims to evaluate...
Sirnaomics Forms High-Profile Scientific Advisory Board to Bolster RNA Therapeutics Pipeline
Sirnaomics Ltd. has formed an external Scientific Advisory Board to guide research and development across its therapeutic pipeline, underscoring its intention to strengthen scientific rigor and regulatory readiness in RNA drug development. The board...
Sirnaomics Wins Strong Shareholder Backing for New 2026 Equity Incentive Schemes
Sirnaomics Ltd. reported that shareholders at its extraordinary general meeting on June 30, 2026 approved new 2026 restricted share unit and share option schemes while terminating the corresponding 2022 plans. The resolutions, including a new scheme...
Sirnaomics Chairman Raises Stake, Signaling Confidence in Growth Prospects
Sirnaomics Ltd. announced that its chairman and executive director, Dr. Poon Hung Fai, has increased his stake in the company by purchasing 20,300 shares on the open market at an average price of about HK$5.00 per share, using personal funds. Followi...
Sirnaomics Wins Strong Shareholder Backing for AGM Resolutions and Capital Mandates
Sirnaomics Ltd. reported that all resolutions at its June 23, 2026 annual general meeting were approved by shareholders via poll, including the adoption of the 2025 audited financial statements and the re-election of several non-executive and indepen...
Sirnaomics Sets EGM to Revamp Equity Incentive Schemes
Sirnaomics Ltd., a Hong Kong-listed biotechnology company specializing in RNA-based therapeutics, develops innovative gene-silencing drugs aimed at global biopharmaceutical markets. Its governance structure includes an executive chairman, a non-execu...
Sirnaomics Reshapes Board Committees After Non-Executive Director Resigns
Sirnaomics Ltd. announced the resignation of non-executive director Ouyang Yunlong, who also stepped down from the audit and remuneration committees, effective June 5, 2026, citing a need to focus on other commitments. The company noted there was no...
Sirnaomics Sets Out Board and Committee Structure
Sirnaomics Ltd. has announced the current composition of its board of directors, led by Executive Director Dr. Poon Hung Fai, who serves as both chairman and chief executive officer. The board also includes one non-executive director and three indepe...
Sirnaomics Clarifies Discounted Share Subscription Terms and Conditionality
Sirnaomics Ltd. has issued a supplemental announcement clarifying details of a planned subscription of new shares under its general mandate, including the benchmarked price of HK$5.77 per share and a subscription price of HK$4.69, representing discou...
Sirnaomics Sets 2026 AGM to Renew Mandates and Re-elect Directors
Sirnaomics has called its annual general meeting for June 23, 2026, in Hong Kong, where shareholders will review and adopt the audited financial statements for the year ended December 31, 2025. The agenda includes re-election of five directors, autho...
Sirnaomics to Raise Capital via Discounted Share Subscription Under General Mandate
Sirnaomics Ltd. has entered into a subscription agreement with an investor to issue 2,435,600 new shares at HK$4.69 each under its existing general mandate, representing about 2.22% of its current share capital and 2.17% on an enlarged basis. The new...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 22, 2026